-
2024-515703-19-00
5
2021-03-02
Peanut allergy
-
2023-505273-33-00
5
2021-02-15
"Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial
(NTM
-
2024-511067-29-00
5
2021-01-25
IgA Nephropathy
-
2022-500811-37-00
4
2021-01-19
Stage II to IV cutaneous squamous cell carcinoma
-
2024-512331-72-00
5
2020-12-22
Squamous Carcinoma of the Anal Canal
-
2024-510745-34-00
10
2020-11-11
Bullous Pemphigoid
-
2024-514495-41-00
5
2020-11-04
Primary Progressive Multiple Sclerosis
-
2023-507222-17-00
5
2020-07-24
Acute Myeloid Leukaemia
-
2023-507846-96-00
5
2020-06-19
Type 2 Diabetes Mellitus
-
2023-505035-12-00
5
2020-06-12
RET fusion−positive, metastatic Non-Small Cell Lung Cancer
-
2022-503014-23-00
6
2020-06-03
Perianal fistulising Crohn´s disease
-
2022-501972-25-00
5
2020-04-06
Locally Advanced Cervical Cancer
-
2024-514018-12-00
9
2020-04-06
female and male adult patients with acute myeloid leukemia (AML) at fi
-
2023-508293-28-00
5
2020-02-20
Dermatomyositis
-
2024-515827-12-00
1
2020-01-28
Acute Myeloid Leukemia (AML)
-
2022-500418-24-00
10
2020-01-17
Locally Recurrent Inoperable or Metastatic Triple Negative Breast Canc
-
2022-502361-15-00
5
2019-12-12
Moderate-to-Severe Plaque Psoriasis
-
2023-506715-18-00
5
2019-12-04
colon cancer stage II, rectal cancer stage II
-
2024-514479-16-00
4
2019-10-28
Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma with
-
2024-513956-14-00
4
2019-09-16
Acute myeloid leukemia
-
2022-502858-14-00
5
2019-09-05
Hypertrophic cardiomyopathy
-
2024-512967-29-00
4
2019-09-03
Hypoparathyroidism (HP) in Adults
-
2023-503956-29-00
5
2019-08-26
Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient
M
-
2022-501970-20-01
5
2019-06-07
Cis-eligible Muscle-invasive bladder cancer.